期刊
ONCOTARGET
卷 7, 期 39, 页码 64089-64099出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.11596
关键词
vascular normalization; anti-angiogenic therapy; sunitinib; neoadjuvant chemotherapy; breast cancer
资金
- National Medical Research Council of Singapore [NMRC/CSI/0015/2009, NMRC/CG/NCIS/2010, NMRC/CG/NCIS/2013]
- WBS fund [R-180-000-016-733]
Background: Prolonged anti-angiogenic therapy destroys tumor vasculature, whereas vascular-normalizing doses may enhance intra-tumoral drug delivery. We hypothesize that low-dose, short-course sunitinib normalizes vasculature, enhancing chemotherapy efficacy. Patients and Methods: In phase Ib, treatment-naive breast cancer patients received four cycles of pre-operative doxorubicin/cyclophosphamide, with sunitinib before each cycle. The optimal dose of sunitinib leading to tumor vessel normalization on immunohistochemistry was identified. In phase II, subjects were randomized to chemotherapy alone or chemotherapy plus sunitinib at the recommended phase II dose (RP2D). Primary endpoint was pathological complete response (pCR) rate. Tumor and functional imaging biomarkers were evaluated serially. Results: In phase Ib (n=9), sunitinib 12.5 mg daily for 7 days before each chemotherapy was established as RP2D. In phase II, patients receiving chemotherapy plus sunitinib (n=24) had similar pCR rates (5.0% versus 4.3%, p=1.00), but a higher incidence of chemotherapy dose delays (33.3% versus 8.7%, p=0.04), compared to those receiving chemotherapy alone (n=25). The addition of sunitinib to chemotherapy significantly increased vascular normalization index (VNI) and decreased lymphatic vessel density (D2-40) on immunohistochemistry [VNI:25.50+/-27.94% versus 49.29+/-31.84%, p=0.034; D2-40:3.29+/-2.70 versus 1.29+/-1.54, p=0.014, baseline versus post-cycle 1], and improved perfusion on DCE-MRI (K-trans: 12.6+/-9.6 mL/100 g/min versus 16.3+/-10.7 mL/100 g/min, baseline versus post-cycle 1, p=0.015). Conversely, immunohistochemical and DCE-MRI parameters were not significantly altered by chemotherapy alone. Conclusion: Low-dose, short-course sunitinib prior to anthracycline-based chemotherapy in breast cancer patients did not improve pCR and increased chemotherapy dose delays. However, the addition of sunitinib induced compelling pharmacodynamic evidence of vascular normalization. Further studies with alternative cytotoxic regimens should be explored.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据